COVID-19 antibody research to illuminate pandemic’s course in Northern California
Researchers with Kaiser Permanente are launching a study using blood tests for antibodies to the SARS-CoV-2 virus to estimate the prevalence and incidence of COVID-19 disease in Northern California and explore whether antibodies confer protection from recurrent disease.
Kaiser Permanente data key to nation’s COVID-19 vaccine surveillance strategy
Kaiser Permanente’s Vaccine Study Center is leading a key part of the national safety surveillance effort for the COVID-19 vaccines, tracking patient data for serious side effects.
No serious side effects for mRNA COVID-19 vaccines in young children
A review of more than 245,000 doses of mRNA COVID-19 vaccines given to young children (most of them age 4 and younger) found no indications of serious side effects.
Messages from doctors increased COVID-19 vaccination among Black, Latino elders
Elderly Black and Latino people were more likely to get a COVID-19 vaccination after they received an email or letter from their Kaiser Permanente doctor, new research finds.
